Sanofi-a Ventis Deutschland Gmbh

Thomas Leeuw

Ekkehard Leberer

Eckart Bartnik

Joerg Czech

Andreas R Klatt

Sebastian Barradeau

Allegra Ritscher

The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

Use of PAK inhibitor for the treatment of a joint disease

The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutatedcell is used whose endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed functionally, but which expresses heterologously a eukaryotic potassium channel to be studied. Other subject matters of the invention are mutatedcells which do not express TRK1, TRK2 and TOK1, and the preparation and use of these mutatedcells.

[object Object]

The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

Growing community of inventors

Greifenberg, Germany

Thomas Leeuw